To validate TGF-β1 as a potential pharmacological target, we explored its deficit in PBMCs as an ex vivo surrogate model for identifying pharmacological targets in AD-related cognitive dysfunction (Rodrigues et al., 2014; Esteras et al., 2016). Here, TGFB1 is linked to Alzheimer disease.